News
NICE says 'no' to regular NHS funding for Roche's Tecentriq ...
NICE has said Roche's Tecentriq (atezolizumab) should not get regular NHS funding in first draft guidance as a treatment for metastastic triple negative breast cancer (TNBC), saying that it
